These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 14587861)

  • 1. Breast cancer prevention trials using retinoids.
    Decensi A; Serrano D; Bonanni B; Cazzaniga M; Guerrieri-Gonzaga A
    J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):19-30. PubMed ID: 14587861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with retinoids for breast cancer chemoprevention.
    Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
    Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of breast cancer with fenretinide.
    Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
    Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenretinide and cancer prevention.
    Torrisi R; Decensi A
    Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoids and breast cancer prevention.
    Bonanni B; Lazzeroni M
    Recent Results Cancer Res; 2009; 181():77-82. PubMed ID: 19213560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoprevention of breast cancer: the Italian experience.
    Decensi A; Bonanni B; Guerrieri-Gonzaga A; Torrisi R; Manetti L; Robertson C; De Palo G; Formelli F; Costa A; Veronesi U
    J Cell Biochem Suppl; 2000; 34():84-96. PubMed ID: 10762020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Fabian CJ; Kimler BF
    Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
    Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
    Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
    [No Abstract]   [Full Text] [Related]  

  • 17. Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials.
    Veronesi U; Decensi A
    J Natl Cancer Inst; 2001 Apr; 93(7):486-8. PubMed ID: 11287432
    [No Abstract]   [Full Text] [Related]  

  • 18. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
    Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
    Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fenretinide on ovarian carcinoma occurrence.
    De Palo G; Mariani L; Camerini T; Marubini E; Formelli F; Pasini B; Decensi A; Veronesi U
    Gynecol Oncol; 2002 Jul; 86(1):24-7. PubMed ID: 12079295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.